allergic reaction semaglutide JAAD Case Reports published a dedicated Virtual Special Issue focusing on the intersection of GLP-1 agonists and cutaneous disease. We highlight this Case Report of a 46-year-old woman presented with a 4-year Semaglutide Injection Site Stinging: Causes

For example, AstraZeneca recently spent $2 billion to license an experimental pill that might have fewer side effects than the injectable treatments

However, compounded drugs are not FDA approved, which means FDA does not review them for safety, effectiveness or quality before they are marketed

Many Patients Will Need New Documentation Patients should schedule appointments ASAP to update: Diagnosis lists BMI and weight records Comorbidity documentation Past medication failures 2

GLP-1 Agonists and Kidney Protection: the emerging renal signal and how it fits care decisions

Among these conditions are reactive oxygen species (ROS), nitric oxide (NO), altered expression of growth factors, and calcium signaling